Evidence map›Paper›PMID 35336011›Full record

ArticlePharmaceutics2022

Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles.

Ernest L Vallorz, David Encinas-Basurto, Rick G Schnellmann, Heidi M Mansour

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Tumor-Targeted Delivery Therapy Based on PLGA Nanoparticles.Journal of functional biomaterials · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ernest L VallorzSkaggs Pharmaceutical Sciences Center, The University of Arizona R. Ken Coit College of Pharmacy, 1703 E Mabel St., Tucson, AZ 85721, USA.ORCID 0000-0002-5994-1265
David Encinas-BasurtoSkaggs Pharmaceutical Sciences Center, The University of Arizona R. Ken Coit College of Pharmacy, 1703 E Mabel St., Tucson, AZ 85721, USA.
Rick G SchnellmannSkaggs Pharmaceutical Sciences Center, The University of Arizona R. Ken Coit College of Pharmacy, 1703 E Mabel St., Tucson, AZ 85721, USA.ORCID 0000-0001-6226-6064
Heidi M MansourSkaggs Pharmaceutical Sciences Center, The University of Arizona R. Ken Coit College of Pharmacy, 1703 E Mabel St., Tucson, AZ 85721, USA.ORCID 0000-0003-3993-9210
University of Arizona · US

Funding

W. M. Keck Foundation 0
6 · The paper itself

Abstract

Polymeric nanoparticles' drug delivery systems represent a promising platform for targeted controlled release since they are capable of improving the bioavailability and tissue localization of drugs compared to traditional means of administration. Investigation of key parameters of nanoparticle preparation and their impact on performance, such as size, drug loading, and sustained release, is critical to understanding the synthesis parameters surrounding a given nanoparticle formulation. This comprehensive and systematic study reports for the first time and focuses on the development and characterization of formoterol polymeric nanoparticles that have potential application in a variety of acute and chronic diseases. Nanoparticles were prepared by a variety of solvent emulsion methods with varying modifications to the polymer and emulsion system with the aim of increasing drug loading and tuning particle size for renal localization and drug delivery. Maximal drug loading was achieved by amine modification of polyethylene glycol (PEG) conjugated to the poly(lactic-co-glycolic acid) (PLGA) backbone. The resulting formoterol PEGylated PLGA polymeric nanoparticles were successfully lyophilized without compromising size distribution by using either sucrose or trehalose as cryoprotectants. The physicochemical characteristics of the nanoparticles were examined comprehensively, including surface morphology, solid-state transitions, crystallinity, and residual water content. In vitro formoterol drug release characteristics from the PEGylated PLGA polymeric nanoparticles were also investigated as a function of both polymer and emulsion parameter selection, and release kinetics modeling was successfully applied.

Indexed as

aminebiocompatiblebiodegradabledrug release kinetics modelingemulsionin vitronanoparticlePEGylationPLGA diblock copolymerPluronic triblock copolymerpolyvinyl alcohol (PVA)solid-state characterizationsucrosetrehalose

Identifiers

PMID35336011
PMCPMC8955426
OpenAlexW4220876843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.